Guideline Summary for Diagnosis and Management of Esophageal Dysmotility

Diagnostic Workup

• Perform upper endoscopy with biopsies of the distal, mid, and proximal esophagus to exclude eosinophilic esophagitis, structural lesions, and mucosal disease that can mimic dysmotility. 1
• Obtain high‑resolution manometry using solid‑food swallows (in addition to water swallows) to better replicate eating symptoms and uncover pathology. 1

Management of Achalasia and EGJ Outflow Obstruction

• When POEM is not feasible, consider laparoscopic fundoplication with a partial (e.g., Toupet) wrap, especially in patients with documented esophageal hypomotility. 2

Management of Spastic Disorders (Distal Esophageal Spasm, Hypercontractile Esophagus)

• Initiate proton‑pump inhibitor therapy (e.g., omeprazole 20–40 mg twice daily) when gastro‑esophageal reflux symptoms coexist, which is common in this population. 2
• Use baclofen (5–20 mg three times daily) for predominant regurgitation or belching, with monitoring for central nervous system and gastrointestinal side effects. 2
• Add low‑dose tricyclic antidepressants (amitriptyline 10–25 mg at bedtime, titrated up to 50 mg) to treat chest pain or esophageal hypersensitivity. 2
• Refer patients with hypervigilance or significant psychological contributors to cognitive‑behavioral therapy, esophageal‑directed hypnotherapy, or diaphragmatic breathing techniques. 2

Management of Ineffective Esophageal Motility and Absent Contractility

• Prescribe proton‑pump inhibitor therapy because concurrent gastro‑esophageal reflux disease frequently worsens symptoms. 2
• Evaluate for delayed gastric emptying with gastric emptying scintigraphy when clinical features suggest gastroparesis. 2
• Reserve prokinetic agents only for patients with objectively documented gastroparesis, as they have not demonstrated benefit for esophageal dysmotility alone. 2
• Avoid a full‑wrap (Nissen) fundoplication; if anti‑reflux surgery is required, use a partial wrap to reduce the risk of postoperative dysphagia. 2

Management of Eosinophilic Esophagitis with Dysmotility

• Begin topical corticosteroid therapy (e.g., budesonide 1 mg twice daily mixed with a sweetener or fluticasone 880 µg twice daily swallowed) for 8–12 weeks to treat eosinophilic inflammation. 1
• Perform a follow‑up endoscopy with biopsies at 8–12 weeks to assess histologic response, recognizing that symptom improvement does not reliably indicate mucosal healing. 1
• If a stricture or narrowing persists despite histologic remission, conduct graded balloon dilation to a target diameter of 15–18 mm. 3

Management of Refractory Symptoms

• Obtain ambulatory 24‑hour pH‑impedance monitoring while on PPI therapy to differentiate ongoing acid or non‑acid reflux, reflux hypersensitivity, or behavioral disorders (e.g., rumination, supragastric belching). 2
• Repeat high‑resolution manometry with solid‑food swallows when prior studies were limited to water swallows, as this increases diagnostic yield. 1
• Re‑evaluate for esophageal hypersensitivity or hypervigilance and intensify neuromodulator therapy or behavioral interventions as needed. 2

Post‑Surgical Dysmotility

• For dysphagia after fundoplication, perform endoscopy, manometry, pH testing, and barium swallow to confirm wrap integrity before any therapeutic intervention. 3
• If the wrap is intact, consider graded balloon dilation to 30–40 mm to relieve dysphagia. 3
• Address any concurrent delayed gastric emptying to lessen the need for repeat dilations. 3

Anastomotic Strictures

• Use bougie or balloon dilation as first‑line therapy, aiming for a final lumen of 15–18 mm. 3
• For refractory strictures, inject triamcinolone (40 mg/mL in four quadrants) immediately before dilation, acknowledging the increased risk of candidiasis. 3
• Needle‑knife incision in four quadrants provides comparable safety to dilation and yields sustained luminal patency in 61.5 % of patients at 12 months versus 19.8 % with dilation alone. 3

Critical Pitfalls

• Do not rely solely on patient‑reported symptom improvement to gauge treatment response in eosinophilic esophagitis; approximately 41 % of patients may feel better without histologic remission. 1
• Do not perform a total (Nissen) fundoplication in individuals with documented esophageal hypomotility or reduced peristaltic reserve; a partial wrap is recommended. 2

Esophageal Dysmotility Treatment Guidelines

Initial Diagnostic Workup

• The American College of Radiology recommends performing a biphasic barium esophagram as the initial diagnostic test, which has 80-89% sensitivity and 79-91% specificity for detecting esophageal motility disorders compared to manometry 4, 5
• The American Gastroenterological Association suggests conducting upper endoscopy with biopsies at two levels to exclude structural lesions, eosinophilic esophagitis, and mucosal disease that may mimic dysmotility 6
• High-resolution manometry (HRM) is recommended as the definitive test to characterize the specific motility disorder pattern and guide treatment decisions 7, 5
• The European Society for Gastrointestinal Endoscopy advises ruling out medication-induced dysmotility by reviewing all current medications, particularly opioids, cyclizine, and anticholinergics which commonly cause esophageal dysmotility 8

Pharmacological Management

• The American College of Gastroenterology recommends initiating proton pump inhibitors (PPIs) as initial therapy, especially when symptoms overlap with gastroesophageal reflux disease, which frequently coexists with motility disorders 7
• Smooth muscle relaxants, including calcium channel antagonists or nitrates, may be considered for spastic disorders, though clinical benefit is often limited despite manometric improvement 7
• The American Neurogastroenterology and Motility Society suggests trialing neuromodulators, such as tricyclic antidepressants, for patients with chest pain or hypersensitivity components 7
• Baclofen (GABA-B agonist) may be used for regurgitation and belch-predominant symptoms, though monitoring for CNS and GI side effects is necessary 7

Endoscopic Interventions

• The American Society for Gastrointestinal Endoscopy recommends considering endoscopic botulinum toxin injection as an effective treatment for esophageal spasms, particularly in patients who fail pharmacological therapy 7
• Esophageal dilation may be performed for patients with associated strictures or narrowing, using balloon dilation or bougie dilators guided by wire 7
• For eosinophilic esophagitis with dysmotility, starting topical steroids before dilation when possible is recommended, as preliminary topical steroids followed by dilation is more cost-effective than dilation alone 9, 10

Advanced Endoscopic and Surgical Options

• The Society of American Gastrointestinal and Endoscopic Surgeons recommends considering Per-Oral Endoscopic Myotomy (POEM) as the preferred treatment for type III achalasia (achalasia with spasm) and select cases of refractory distal esophageal spasm 7
• POEM should only be performed by experienced physicians in high-volume centers, as 20-40 procedures are needed to achieve competence 7
• Patients should be counseled about the high risk of post-POEM reflux esophagitis requiring potential indefinite PPI therapy and/or surveillance endoscopy 7

Behavioral and Adjunctive Interventions

• The American Psychological Association recommends implementing cognitive behavioral therapy (CBT), esophageal-directed hypnotherapy, or diaphragmatic breathing for disorders with associated hypervigilance or hypersensitivity 7

Special Considerations for Specific Etiologies

• The European Society for Pediatric Gastroenterology, Hepatology and Nutrition recommends offering dilatation along with disease modification using diet, topical steroids, or other drugs rather than dilation alone for eosinophilic esophagitis with dysmotility 9, 11
• Maintenance treatment with topical steroids or dietary elimination should be continued after dilation to prevent symptom recurrence 10

Monitoring Treatment Response

• The American Gastroenterological Association recommends performing follow-up endoscopy with biopsy while on treatment to assess response, as symptoms may not correlate with histological activity 12
• Oesophageal physiological testing (high-resolution manometry with solid swallows) may be considered in patients with ongoing dysphagia despite histological remission and absence of fibrostenotic disease 12